Browse Studies — Arctuva

Phase 2

ISA2 to Master Protocol ARGX-999-2-MG-2000 - an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are an…

AChR-Ab Seropositive Generalized Myasthenia GravisMyasthenia Gravis (MG)MG - Myasthenia Gravis+1 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

argenxNCT07673627

AXIS Autoimmune Neurology Registry

The goal of the AXIS Autoimmune Neurology Registry is to learn about the experiences of adults living with autoimmune neurological disorders, starting with mya…

Myasthenia Gravis (MG)Myasthenia Gravis, GeneralizedMyasthenia Gravis, Ocular+12 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Autoimmune Neurology AllianceNCT07761026

Pilot Study: Feasibility of Remote Monitoring of Patients With Myasthenia Gravis

Myasthenia gravis is an autoimmune neuromuscular disorder characterized by fluctuating weakness, which can worsen suddenly without a clear predictor. The hypot…

Myasthenia Gravis (MG)

Estimated

~$10 – $750

Actual pay is set by the research site.

George Washington UniversityNCT07787247